Pharma & Biotech

This report provides an overview of the digital pathology market from 2023 to 2028. The digital pathology market, as defined in this report, is comprised of revenue from instruments and software sold to clinical, academic, biopharma, and CRO customers, along with service revenues generated by CROs and reference labs.* This market is highly fragmented today, with top vendors providing multiple tools relevant for different aspects of the digital pathology workflow (i.e., slide scanning, slide viewing, image analysis, report generation, and image storage) and many other mid-sized and smaller-sized players that provide tools for individual aspects of the digital pathology workflow (i.e., only AI tools). Many players have formed partnerships with other DP providers, which will likely impact growth for some of the small to mid-sized players as consolidation occurs.

DeciBio conducted 10 interviews with stakeholders at pharmaceutical companies to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted 10 interviews with academic researchers and biopharma executives to explore how advanced and next-generation proteomics tools have been adopted into research efforts today

DeciBio conducted 11 interviews with KOLs at pharmaceutical companies to understand how pharma spends their money in support of therapeutic / precision medicine development initiatives today, and how these investments may change in the future